Literature DB >> 24769073

LRH1 promotes pancreatic cancer metastasis.

Qiushi Lin1, Arihiro Aihara2, Waihong Chung2, Yu Li3, Xuesong Chen4, Zheping Huang1, Shaofan Weng5, Rolf I Carlson2, Christina Nadolny1, Jack R Wands2, Xiaoqun Dong6.   

Abstract

The transcriptional factor liver receptor homolog 1 (LRH1) regulates pancreatic development, and may participate in pancreatic oncogenesis through activation of growth factor signaling transduction cascades. We measured transcriptional activity of β-catenin in response to LRH1 stimulation by a Topflash reporter assay. The pancreatic cancer (PC) phenotype was then characterized by cell migration, wound healing, invasion, and sphere formation in vitro, as well as tumor formation and distant metastatic spread in vivo. We compared results between vector control and LRH1-overexpressing stable PC cell lines. In addition, tumor burden, angiogenesis, histologic characteristics, and hepatic spread were assessed in orthotopic and experimental liver metastatic murine models. Expression of downstream LRH1 related genes was evaluated by Western blot and immunohistochemistry in PC cell lines and human tumor specimens. Specific inhibition of LRH1 expression and function was accomplished by shRNAs "knockdown" experiments. It was found that LRH1 enhanced transcriptional activity of β-catenin and the expression of downstream target genes (c-Myc, MMP2/9), as well as promoted migration, wound healing, invasion, and sphere formation of PC cell lines. Specific inhibition of LRH1 by shRNAs reduced cell migration, invasion, sphere formation and expression of c-Myc and MMP2/9 target genes. Mice injected with LRH1 overexpressing stable PC cells developed tumors with increased size and exhibited striking hepatic metastatic spread. More important, LRH1 was overexpressed in PC tumors compared to adjacent normal pancreas. Our findings demonstrate that LRH1 overexpression is associated with increased PC growth and metastatic spread, indicating that LRH1-targeted therapy could inhibit tumor progression.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Liver receptor homolog 1; MMP2; MMP9; Pancreatic cancer; c-Myc

Mesh:

Substances:

Year:  2014        PMID: 24769073     DOI: 10.1016/j.canlet.2014.04.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.

Authors:  Jean-Luc Van Laethem; Hanno Riess; Jacek Jassem; Michael Haas; Uwe M Martens; Colin Weekes; Marc Peeters; Paul Ross; John Bridgewater; Bohuslav Melichar; Stefano Cascinu; Piotr Saramak; Patrick Michl; David Van Brummelen; Alberto Zaniboni; Wollf Schmiegel; Svein Dueland; Marius Giurescu; Vittorio L Garosi; Katrin Roth; Anke Schulz; Henrik Seidel; Prabhu Rajagopalan; Michael Teufel; Barrett H Childs
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

2.  Effect of NR5A2 inhibition on pancreatic cancer stem cell (CSC) properties and epithelial-mesenchymal transition (EMT) markers.

Authors:  Zhaofan Luo; Yanan Li; Mingxin Zuo; Chang Liu; Weihua Tian; Dong Yan; Huamin Wang; Donghui Li
Journal:  Mol Carcinog       Date:  2017-01-12       Impact factor: 4.784

3.  Silencing LRH-1 in colon cancer cell lines impairs proliferation and alters gene expression programs.

Authors:  James R Bayrer; Sridevi Mukkamala; Elena P Sablin; Paul Webb; Robert J Fletterick
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

Review 4.  Liver receptor homolog-1 (LRH-1): a potential therapeutic target for cancer.

Authors:  Christina Nadolny; Xiaoqun Dong
Journal:  Cancer Biol Ther       Date:  2015-05-07       Impact factor: 4.742

5.  Effects of LncRNA-HOST2 on cell proliferation, migration, invasion and apoptosis of human hepatocellular carcinoma cell line SMMC-7721.

Authors:  Run-Tian Liu; Jing-Lin Cao; Chang-Qing Yan; Yang Wang; Cong-Jing An; Hai-Tao Lv
Journal:  Biosci Rep       Date:  2017-04-20       Impact factor: 3.840

6.  LRH1 Promotes Tumor Cell Proliferation and Migration and Is Correlated With Poor Prognosis in Ovarian Cancer.

Authors:  Wenzhou Sun; Qingtao Shi; Jiaxin Li; Jinmeng Li; Libo Yu
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

7.  Aspartate β-Hydroxylase expression promotes a malignant pancreatic cellular phenotype.

Authors:  Xiaoqun Dong; Qiushi Lin; Arihiro Aihara; Yu Li; Chiung-Kuei Huang; Waihong Chung; Qi Tang; Xuesong Chen; Rolf Carlson; Christina Nadolny; Gregory Gabriel; Mark Olsen; Jack R Wands
Journal:  Oncotarget       Date:  2015-01-20

8.  Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.

Authors:  Chiung-Kuei Huang; Yoshifumi Iwagami; Arihiro Aihara; Waihong Chung; Suzanne de la Monte; John-Michael Thomas; Mark Olsen; Rolf Carlson; Tunan Yu; Xiaoqun Dong; Jack Wands
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

9.  Nuclear receptor NR5A2 controls neural stem cell fate decisions during development.

Authors:  Athanasios Stergiopoulos; Panagiotis K Politis
Journal:  Nat Commun       Date:  2016-07-22       Impact factor: 14.919

10.  The Orphan Nuclear Receptor Liver Homolog Receptor-1 (Nr5a2) Regulates Ovarian Granulosa Cell Proliferation.

Authors:  Marie-Charlotte Meinsohn; Fanny Morin; Kalyne Bertolin; Raj Duggavathi; Kristina Schoonjans; Bruce D Murphy
Journal:  J Endocr Soc       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.